4 results
Primary objectivesTo evaluate the effect of the CYP1A2 inhibitor, fluvoxamine, on steady state pharmacokinetics of TKI258 in patients with advanced solid tumors, excluding breast cancerSecondary objectives• To characterize the safety and…
1. Optimize breath collection settings for optimal use in children.2. Evaluate the use of breath biomarkers for the prediction of therapeutic response in asthmatic children.
In this study we will look at how quickly and to what extent the study compound MEN1611 is absorbed, transported, and eliminated from the body (this is called pharmacokinetics) and how this is influenced by the approved drug itraconazole fluvoxamine…
The project*s overarching aim is to diminish respiratory disease burden in moderate-late preterm born infants in their first year of life.We have formulated the following specific aims: 1. Determine whether bacterial lysates reduce the number and/or…